Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
A plea for TDM-based optimisation for treatment of Crohn's disease
Margien L Seinen, Nanne K de Boer
European Journal of Gastroenterology & Hepatology
|
August 1, 2018
Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy
Melek Simsek, Margien L Seinen, Nanne K H de Boer
Expert Opinion on Drug Metabolism & Toxicology
|
March 21, 2019
Key insights from therapeutic drug monitoring in Crohn's disease patients
Margien L Seinen, Nanne K De Boer, Adriaan A van Bodegraven
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 15, 2013
Reply: To PMID 23333660
Margien L Seinen, Nanne K H De Boer, Adriaan A van Bodegraven
Cancer Research
|
February 9, 2013
Oxidation-mediated DNA crosslinking contributes to toxicity of 6-thioguanine in human cells -- letter
Nanne K H de Boer, Dirk P van Asseldonk, Margien L Seinen, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
October 6, 2010
Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice
Margien L Seinen, Dirk P van Asseldonk, Chris J J Mulder, et al.
Molecular Diagnosis & Therapy
|
September 9, 2016
Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy
Margien L Seinen, Geerten P van Nieuw Amerongen, Nanne K H de Boer, et al.
Journal of Crohn'S & Colitis
|
January 21, 2012
Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment
Dirk P van Asseldonk, Margien L Seinen, Nanne K H de Boer, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
February 25, 2020
The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review
Ahmed B Bayoumy, Melek Simsek, Margien L Seinen, et al.
Therapeutic Drug Monitoring
|
May 10, 2016
Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease
Berrie Meijer, Margien L Seinen, Niek N W Leijte, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
A plea for TDM-based optimisation for treatment of Crohn's disease
Margien L Seinen, Nanne K de Boer
European Journal of Gastroenterology & Hepatology
|
August 1, 2018
Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy
Melek Simsek, Margien L Seinen, Nanne K H de Boer
Expert Opinion on Drug Metabolism & Toxicology
|
March 21, 2019
Key insights from therapeutic drug monitoring in Crohn's disease patients
Margien L Seinen, Nanne K De Boer, Adriaan A van Bodegraven
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 15, 2013
Reply: To PMID 23333660
Margien L Seinen, Nanne K H De Boer, Adriaan A van Bodegraven
Cancer Research
|
February 9, 2013
Oxidation-mediated DNA crosslinking contributes to toxicity of 6-thioguanine in human cells -- letter
Nanne K H de Boer, Dirk P van Asseldonk, Margien L Seinen, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
October 6, 2010
Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice
Margien L Seinen, Dirk P van Asseldonk, Chris J J Mulder, et al.
Molecular Diagnosis & Therapy
|
September 9, 2016
Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy
Margien L Seinen, Geerten P van Nieuw Amerongen, Nanne K H de Boer, et al.
Journal of Crohn'S & Colitis
|
January 21, 2012
Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment
Dirk P van Asseldonk, Margien L Seinen, Nanne K H de Boer, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
February 25, 2020
The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review
Ahmed B Bayoumy, Melek Simsek, Margien L Seinen, et al.
Therapeutic Drug Monitoring
|
May 10, 2016
Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease
Berrie Meijer, Margien L Seinen, Niek N W Leijte, et al.
Page
of 3